Zydus Cadila has received tentative approval from the US Food & Drug Administration ( USFDA) to market Palbociclib Capsules, (US RLD: Ibrance Capsules) in the strengths of 75 mg, 100 mg, and 125 mg. Palbociclib is an anti-cancer medicine that interferes with the growth and spread of cancer cells in the body. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 302 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1510.00 |
Dr. Reddys Lab | 6089.30 |
Cipla | 1533.80 |
Zydus Lifesciences | 1082.55 |
Lupin | 1630.75 |
View more.. |